This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): BI10773, BI 10773
Description: BI 10773 is an oral, sodium-dependent glucose transporter-2 inhibitor (SGLT-2 inhibitor). SGLT-2 inhibitors express their therapeutic effect mainly by eliminating excess blood glucose via the urine.
For Jardiance, gross margin is split equally with Boehringer Ingelheim. Lilly's revenue has been multiplied by two to estimate total net sales. Historical revenues include Glyxambi.
In January 2011, Eli Lilly and Company and Boehringer Ingelheim announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim's two oral diabetes agentslinagliptin and BI10773as well as Lilly's two basal insulin analoguesLY2605541 and LY2963016as well as the option to co-develop and co-commercialize Lilly's anti-TGF-beta monoclonal antibody.
Under the terms of the agreement, Lilly will make an initial one-time payment to Boehringer Ingelheim of euro 300 million. Boehringer Ingelheim will be eligible to receive up to a total of euro 625 million in success-based regulatory milestones for linagliptin and BI10773. Lilly will be...See full deal structure in Biomedtracker
Partners: Eli Lilly & Company Lupin Limited
Additional information available to subscribers only: